Connor Clark & Lunn Investment Management Ltd. Has $21.56 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Connor Clark & Lunn Investment Management Ltd. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 115.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,511 shares of the biopharmaceutical company’s stock after acquiring an additional 11,008 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $21,562,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. SteelPeak Wealth LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 692 shares in the last quarter. Atria Investments Inc grew its holdings in Regeneron Pharmaceuticals by 12.2% in the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after purchasing an additional 941 shares during the period. Mizuho Securities USA LLC increased its stake in Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares in the last quarter. Tri Locum Partners LP raised its holdings in shares of Regeneron Pharmaceuticals by 104.5% during the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares during the period. Finally, Tidal Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after purchasing an additional 711 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on REGN. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Finally, Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ:REGN opened at $743.35 on Thursday. The company has a market cap of $81.69 billion, a price-to-earnings ratio of 18.40, a PEG ratio of 2.81 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 12 month low of $736.01 and a 12 month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $961.76 and a 200 day moving average price of $1,030.14.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.